A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo.
about
Leptin increases striatal dopamine D2 receptor binding in leptin-deficient obese (ob/ob) mice.Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes.Bromocriptine increased operant responding for high fat food but decreased chow intake in both obesity-prone and resistant rats.Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes.Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes.Bromocriptine in type 2 diabetes mellitusPresent and Prospective Pharmacotherapy for the Management of Patients with Type 2 DiabetesThe conductor of the autonomic orchestra.Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects.Efficacy of bromocriptine on glycemic and metabolic control of prediabetic patients.Association Between Prolactin and Incidence of Cardiovascular Risk Factors in the Framingham Heart StudyManagement of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes.Effects of cabergoline on blood glucose levels in type 2 diabetic patients: A double-blind controlled clinical trial.Brain signaling systems in the Type 2 diabetes and metabolic syndrome: promising target to treat and prevent these diseases.Efficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus: a randomized open labeled phase IV clinical trial.Bromocriptine--unique formulation of a dopamine agonist for the treatment of type 2 diabetes.Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus.Diabetes pharmacotherapy in 2012: considerations in medication selection.A review of the efficacy and safety of oral antidiabetic drugsCardiovascular effects of anti-diabetes drugs.
P2860
Q33862970-4654FDA1-F1FB-49FD-8BDB-075D34A081EBQ33932712-2A2BAB33-9814-4C88-9887-C9018A3CEBD7Q34476706-96729C16-44E3-44C8-A87C-2926305B3199Q34620547-819ADF69-4979-4731-99E2-F8A4DE005FC9Q35153053-1BBDC77C-BDA6-414D-9773-35AC87C0D995Q35153082-FDD339FE-D34D-4C5E-A88B-762A7909FE72Q35909303-BD928BDB-AAB0-498C-83F2-F7CCA75E703FQ36050086-9D1BA870-0204-499B-A41C-AC94DD2F10E0Q36522638-0DBFCE25-3DF1-4B30-93C2-C8C5EE8997C3Q36560960-C5D38D5A-3B76-49E8-B3A8-78167A2F438EQ36714142-F0B5E10E-F67F-441E-A0B7-80FD2535FE87Q37102861-C2D2C149-84D0-4918-AD8F-D02D7EB78562Q37328780-8F12CD9C-8B03-4127-AFAD-DA4B354EBC4AQ37474214-7BDB4375-3D70-4E0E-B78C-998272FEE52AQ37551483-E3FCAF09-0EEC-4B23-88E3-C90C135813EFQ37661556-6C3416E5-2A37-41C3-AA88-AF1FA6D4DE4DQ37803304-D6F68BA2-23E2-4CB2-B608-23FC81F51F3DQ38036772-01FB135C-3FE8-464B-966A-C3F4567372DCQ38067491-29F16E55-3ED4-4622-835B-E79559AD31D2Q38857056-32A303AA-B328-4BB6-BD77-A343B96254B8
P2860
A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A randomized, double-blind, pl ...... nd either Cycloset or placebo.
@ast
A randomized, double-blind, pl ...... nd either Cycloset or placebo.
@en
type
label
A randomized, double-blind, pl ...... nd either Cycloset or placebo.
@ast
A randomized, double-blind, pl ...... nd either Cycloset or placebo.
@en
prefLabel
A randomized, double-blind, pl ...... nd either Cycloset or placebo.
@ast
A randomized, double-blind, pl ...... nd either Cycloset or placebo.
@en
P2093
P2860
P356
P1476
A randomized, double-blind, pl ...... nd either Cycloset or placebo.
@en
P2093
Anthony Cincotta
Dean Rutty
J Michael Gaziano
Michael Ezrokhi
Richard E Scranton
P2860
P2888
P356
10.1186/1472-6823-7-3
P577
2007-06-25T00:00:00Z
P5875
P6179
1045439376